Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
0.389
-0.007 (-1.74%)
At close: Mar 9, 2026, 4:00 PM EDT
0.400
+0.010 (2.62%)
After-hours: Mar 9, 2026, 7:30 PM EDT
Scienture Holdings Revenue
Scienture Holdings had revenue of $590.05K in the quarter ending September 30, 2025, with 809.71% growth. This brings the company's revenue in the last twelve months to $653.39K, up 207.88% year-over-year. In the year 2024, Scienture Holdings had annual revenue of $136.64K, down -89.98%.
Revenue (ttm)
$653.39K
Revenue Growth
+207.88%
P/S Ratio
24.21
Revenue / Employee
$34,389
Employees
19
Market Cap
15.82M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 136.64K | -1.23M | -89.98% |
| Dec 31, 2023 | 1.36M | 1.06M | 354.61% |
| Dec 31, 2022 | 300.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSCNX News
- 4 weeks ago - SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium - GlobeNewsWire
- 7 weeks ago - SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment - GlobeNewsWire
- 2 months ago - SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA - GlobeNewsWire
- 3 months ago - SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium - GlobeNewsWire
- 3 months ago - Scienture Holdings, Inc. (SCNX) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript - Seeking Alpha
- 3 months ago - SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 - GlobeNewsWire
- 4 months ago - SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans - GlobeNewsWire